bioRxiv (Cold Spring Harbor Laboratory)
June 26, 2026
Paulina Clara Dagnino, Irene Acero-Pousa, Robin Carhart-Harris et al.
preprint
Abstract A central challenge in neuroscience is understanding how the human brain is organised to support optimal functioning and adaptability. One approach to characterise complex brain dynamics is by artificially perturbing whole-brain models. Here, we asked whether whole-brain organisation under perturbation in major depressive disorder (MDD) changes after intervention with psilocybin and...
International Journal of Innovative Technologies in Social Science
June 24, 2026
Aleksandra Łoś, Kacper Szkodziński, Inga Jakubczyk et al.
Introduction: Depressive disorders are one of the greatest public health challenges worldwide, affecting up to 16% of the population over a lifetime and significantly impacting quality of life, disability, and premature mortality. Major depressive disorder (MDD) is a leading cause of disability, despite the availability of numerous treatment options. In 20–50% of patients, traditional...
Journal of Psychopharmacology
June 23, 2026
Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.
BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as...
Research Square
June 19, 2026
Aline Frick, Grace Blest‐hopley, Manesh Grin et al.
preprint
Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...
Annals of Medicine and Surgery
June 18, 2026
Astrit Sabani, Adnan Khatak
Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremental refinements of conventional...
bioRxiv (Cold Spring Harbor Laboratory)
June 16, 2026
Paulina Clara Dagnino, Irene Acero-Pousa, Gorka Zamora-López et al.
1 citation
preprint
Abstract In recent decades, the psychedelic psilocybin has been studied as a potential treatment for major depressive disorder (MDD), offering an alternative to traditional antidepressants. However, the brain changes underlying the clinical effects of different interventions remain unclear. Here, we investigated the effects of psilocybin and a conventional antidepressant, escitalopram, from the...
Psychedelic Medicine
June 16, 2026
Max Wolff, Samuli Kangaslampi, Richard J. Zeifman et al.
This commentary critically examines the interpretation and analytic choices in Goodwin and colleagues’ recent analysis of therapeutic alliance in psilocybin treatment for treatment-resistant depression. While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in...
Journal of Affective Disorders
June 15, 2026
Marc J. Weintraub, Jessica K Jeffrey, Megan Ichinose et al.
Psilocybin-assisted therapy has emerged as a promising treatment for major depressive disorder, but little attention has been paid to the psychotherapy that adjoins psilocybin. Providing an adjunctive psychotherapy that is manualized and evidence-based may make psilocybin treatment more acceptable, effective, and disseminable. We examined the acceptability, feasibility, and clinical outcomes of...
SAIMSARA Journal
June 15, 2026
This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studies with 271241797 total...
Psychiatry International
June 15, 2026
Angel Labra-Lorenzana, Dania Nimbe Lima Sanchez, Christian Alejandro Delaflor-Wagner et al.
Background: This systematic review and meta-analysis evaluates the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for adults with major depressive disorder (MDD). Methods: A PROSPERO-registered search (CRD42024561979) of CENTRAL, Scopus, PsycINFO, and MEDLINE (2010–2024) identified clinical trials assessing PAP. Risk of bias was assessed using RoB 2 for randomized controlled...